 | • レポートコード：QYR2104Z4383 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、92ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,092,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、過活動膀胱治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（抗コリン作用薬、ソリフェナシン、オキシブチニン、ダリフェナシン、フェソテロジン、トルテロジン、トロスピウム、その他）、用途別市場規模（特発膀胱過活動、神経因性膀胱過活動）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・過活動膀胱治療薬の市場動向 ・企業の競争状況、市場シェア ・過活動膀胱治療薬の種類別市場規模（抗コリン作用薬、ソリフェナシン、オキシブチニン、ダリフェナシン、フェソテロジン、トルテロジン、トロスピウム、その他） ・過活動膀胱治療薬の用途別市場規模（特発膀胱過活動、神経因性膀胱過活動） ・過活動膀胱治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・過活動膀胱治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・過活動膀胱治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・過活動膀胱治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・過活動膀胱治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Astellas Pharma, Inc. (Japan)、Pfizer, Inc. (US)、Teva Pharmaceutical Industries Limited (Israel)、Allergan, Plc (Ireland)、Medtronic plc (Ireland)、Mylan N.V. (US)、Endo International plc (Ireland)、Hisamitsu Pharmaceutical Co., Inc. (Japan)、Sanofi (France)、Apotex, Inc. (Canada)、Cogentix Medical, Inc. (US)、Aurobindo Pharma Limited (India)） ・結論 |
Market Analysis and Insights: Global Overactive Bladder Drug Market
The global Overactive Bladder Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Overactive Bladder Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Overactive Bladder Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Overactive Bladder Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Overactive Bladder Drug market.
Global Overactive Bladder Drug Scope and Market Size
Overactive Bladder Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Overactive Bladder Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Anticholinergics
Solifenacin
Oxybutynin
Darifenacin
Fesoterodine
Tolterodine
Trospium
Others
Segment by Application
Idiopathic Bladder Overactivity
Neurogenic Bladder Overactivity
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Astellas Pharma, Inc. (Japan)
Pfizer, Inc. (US)
Teva Pharmaceutical Industries Limited (Israel)
Allergan, Plc (Ireland)
Medtronic plc (Ireland)
Mylan N.V. (US)
Endo International plc (Ireland)
Hisamitsu Pharmaceutical Co., Inc. (Japan)
Sanofi (France)
Allergan, Plc (Ireland)
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Overactive Bladder Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Anticholinergics
1.2.3 Solifenacin
1.2.4 Oxybutynin
1.2.5 Darifenacin
1.2.6 Fesoterodine
1.2.7 Tolterodine
1.2.8 Trospium
1.2.9 Others
1.3 Market by Application
1.3.1 Global Overactive Bladder Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Idiopathic Bladder Overactivity
1.3.3 Neurogenic Bladder Overactivity
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Overactive Bladder Drug Market Perspective (2016-2027)
2.2 Overactive Bladder Drug Growth Trends by Regions
2.2.1 Overactive Bladder Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Overactive Bladder Drug Historic Market Share by Regions (2016-2021)
2.2.3 Overactive Bladder Drug Forecasted Market Size by Regions (2022-2027)
2.3 Overactive Bladder Drug Industry Dynamic
2.3.1 Overactive Bladder Drug Market Trends
2.3.2 Overactive Bladder Drug Market Drivers
2.3.3 Overactive Bladder Drug Market Challenges
2.3.4 Overactive Bladder Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Overactive Bladder Drug Players by Revenue
3.1.1 Global Top Overactive Bladder Drug Players by Revenue (2016-2021)
3.1.2 Global Overactive Bladder Drug Revenue Market Share by Players (2016-2021)
3.2 Global Overactive Bladder Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Overactive Bladder Drug Revenue
3.4 Global Overactive Bladder Drug Market Concentration Ratio
3.4.1 Global Overactive Bladder Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Overactive Bladder Drug Revenue in 2020
3.5 Overactive Bladder Drug Key Players Head office and Area Served
3.6 Key Players Overactive Bladder Drug Product Solution and Service
3.7 Date of Enter into Overactive Bladder Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Overactive Bladder Drug Breakdown Data by Type
4.1 Global Overactive Bladder Drug Historic Market Size by Type (2016-2021)
4.2 Global Overactive Bladder Drug Forecasted Market Size by Type (2022-2027)
5 Overactive Bladder Drug Breakdown Data by Application
5.1 Global Overactive Bladder Drug Historic Market Size by Application (2016-2021)
5.2 Global Overactive Bladder Drug Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Overactive Bladder Drug Market Size (2016-2027)
6.2 North America Overactive Bladder Drug Market Size by Type
6.2.1 North America Overactive Bladder Drug Market Size by Type (2016-2021)
6.2.2 North America Overactive Bladder Drug Market Size by Type (2022-2027)
6.2.3 North America Overactive Bladder Drug Market Size by Type (2016-2027)
6.3 North America Overactive Bladder Drug Market Size by Application
6.3.1 North America Overactive Bladder Drug Market Size by Application (2016-2021)
6.3.2 North America Overactive Bladder Drug Market Size by Application (2022-2027)
6.3.3 North America Overactive Bladder Drug Market Size by Application (2016-2027)
6.4 North America Overactive Bladder Drug Market Size by Country
6.4.1 North America Overactive Bladder Drug Market Size by Country (2016-2021)
6.4.2 North America Overactive Bladder Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Overactive Bladder Drug Market Size (2016-2027)
7.2 Europe Overactive Bladder Drug Market Size by Type
7.2.1 Europe Overactive Bladder Drug Market Size by Type (2016-2021)
7.2.2 Europe Overactive Bladder Drug Market Size by Type (2022-2027)
7.2.3 Europe Overactive Bladder Drug Market Size by Type (2016-2027)
7.3 Europe Overactive Bladder Drug Market Size by Application
7.3.1 Europe Overactive Bladder Drug Market Size by Application (2016-2021)
7.3.2 Europe Overactive Bladder Drug Market Size by Application (2022-2027)
7.3.3 Europe Overactive Bladder Drug Market Size by Application (2016-2027)
7.4 Europe Overactive Bladder Drug Market Size by Country
7.4.1 Europe Overactive Bladder Drug Market Size by Country (2016-2021)
7.4.2 Europe Overactive Bladder Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Overactive Bladder Drug Market Size (2016-2027)
8.2 Asia-Pacific Overactive Bladder Drug Market Size by Type
8.2.1 Asia-Pacific Overactive Bladder Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Overactive Bladder Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Overactive Bladder Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Overactive Bladder Drug Market Size by Application
8.3.1 Asia-Pacific Overactive Bladder Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Overactive Bladder Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Overactive Bladder Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Overactive Bladder Drug Market Size by Region
8.4.1 Asia-Pacific Overactive Bladder Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Overactive Bladder Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Overactive Bladder Drug Market Size (2016-2027)
9.2 Latin America Overactive Bladder Drug Market Size by Type
9.2.1 Latin America Overactive Bladder Drug Market Size by Type (2016-2021)
9.2.2 Latin America Overactive Bladder Drug Market Size by Type (2022-2027)
9.2.3 Latin America Overactive Bladder Drug Market Size by Type (2016-2027)
9.3 Latin America Overactive Bladder Drug Market Size by Application
9.3.1 Latin America Overactive Bladder Drug Market Size by Application (2016-2021)
9.3.2 Latin America Overactive Bladder Drug Market Size by Application (2022-2027)
9.3.3 Latin America Overactive Bladder Drug Market Size by Application (2016-2027)
9.4 Latin America Overactive Bladder Drug Market Size by Country
9.4.1 Latin America Overactive Bladder Drug Market Size by Country (2016-2021)
9.4.2 Latin America Overactive Bladder Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Overactive Bladder Drug Market Size (2016-2027)
10.2 Middle East & Africa Overactive Bladder Drug Market Size by Type
10.2.1 Middle East & Africa Overactive Bladder Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Overactive Bladder Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Overactive Bladder Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Overactive Bladder Drug Market Size by Application
10.3.1 Middle East & Africa Overactive Bladder Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Overactive Bladder Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Overactive Bladder Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Overactive Bladder Drug Market Size by Country
10.4.1 Middle East & Africa Overactive Bladder Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Overactive Bladder Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Astellas Pharma, Inc. (Japan)
11.1.1 Astellas Pharma, Inc. (Japan) Company Details
11.1.2 Astellas Pharma, Inc. (Japan) Business Overview
11.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Introduction
11.1.4 Astellas Pharma, Inc. (Japan) Revenue in Overactive Bladder Drug Business (2016-2021)
11.1.5 Astellas Pharma, Inc. (Japan) Recent Development
11.2 Pfizer, Inc. (US)
11.2.1 Pfizer, Inc. (US) Company Details
11.2.2 Pfizer, Inc. (US) Business Overview
11.2.3 Pfizer, Inc. (US) Overactive Bladder Drug Introduction
11.2.4 Pfizer, Inc. (US) Revenue in Overactive Bladder Drug Business (2016-2021)
11.2.5 Pfizer, Inc. (US) Recent Development
11.3 Teva Pharmaceutical Industries Limited (Israel)
11.3.1 Teva Pharmaceutical Industries Limited (Israel) Company Details
11.3.2 Teva Pharmaceutical Industries Limited (Israel) Business Overview
11.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Introduction
11.3.4 Teva Pharmaceutical Industries Limited (Israel) Revenue in Overactive Bladder Drug Business (2016-2021)
11.3.5 Teva Pharmaceutical Industries Limited (Israel) Recent Development
11.4 Allergan, Plc (Ireland)
11.4.1 Allergan, Plc (Ireland) Company Details
11.4.2 Allergan, Plc (Ireland) Business Overview
11.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Introduction
11.4.4 Allergan, Plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021)
11.4.5 Allergan, Plc (Ireland) Recent Development
11.5 Medtronic plc (Ireland)
11.5.1 Medtronic plc (Ireland) Company Details
11.5.2 Medtronic plc (Ireland) Business Overview
11.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Introduction
11.5.4 Medtronic plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021)
11.5.5 Medtronic plc (Ireland) Recent Development
11.6 Mylan N.V. (US)
11.6.1 Mylan N.V. (US) Company Details
11.6.2 Mylan N.V. (US) Business Overview
11.6.3 Mylan N.V. (US) Overactive Bladder Drug Introduction
11.6.4 Mylan N.V. (US) Revenue in Overactive Bladder Drug Business (2016-2021)
11.6.5 Mylan N.V. (US) Recent Development
11.7 Endo International plc (Ireland)
11.7.1 Endo International plc (Ireland) Company Details
11.7.2 Endo International plc (Ireland) Business Overview
11.7.3 Endo International plc (Ireland) Overactive Bladder Drug Introduction
11.7.4 Endo International plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021)
11.7.5 Endo International plc (Ireland) Recent Development
11.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
11.8.1 Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Details
11.8.2 Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview
11.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Introduction
11.8.4 Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue in Overactive Bladder Drug Business (2016-2021)
11.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
11.9 Sanofi (France)
11.9.1 Sanofi (France) Company Details
11.9.2 Sanofi (France) Business Overview
11.9.3 Sanofi (France) Overactive Bladder Drug Introduction
11.9.4 Sanofi (France) Revenue in Overactive Bladder Drug Business (2016-2021)
11.9.5 Sanofi (France) Recent Development
11.10 Apotex, Inc. (Canada)
11.10.1 Apotex, Inc. (Canada) Company Details
11.10.2 Apotex, Inc. (Canada) Business Overview
11.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Introduction
11.10.4 Apotex, Inc. (Canada) Revenue in Overactive Bladder Drug Business (2016-2021)
11.10.5 Apotex, Inc. (Canada) Recent Development
11.11 Cogentix Medical, Inc. (US)
11.11.1 Cogentix Medical, Inc. (US) Company Details
11.11.2 Cogentix Medical, Inc. (US) Business Overview
11.11.3 Cogentix Medical, Inc. (US) Overactive Bladder Drug Introduction
11.11.4 Cogentix Medical, Inc. (US) Revenue in Overactive Bladder Drug Business (2016-2021)
11.11.5 Cogentix Medical, Inc. (US) Recent Development
11.12 Aurobindo Pharma Limited (India)
11.12.1 Aurobindo Pharma Limited (India) Company Details
11.12.2 Aurobindo Pharma Limited (India) Business Overview
11.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Introduction
11.12.4 Aurobindo Pharma Limited (India) Revenue in Overactive Bladder Drug Business (2016-2021)
11.12.5 Aurobindo Pharma Limited (India) Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Overactive Bladder Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Anticholinergics
Table 3. Key Players of Solifenacin
Table 4. Key Players of Oxybutynin
Table 5. Key Players of Darifenacin
Table 6. Key Players of Fesoterodine
Table 7. Key Players of Tolterodine
Table 8. Key Players of Trospium
Table 9. Key Players of Others
Table 10. Global Overactive Bladder Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 11. Global Overactive Bladder Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 12. Global Overactive Bladder Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 13. Global Overactive Bladder Drug Market Share by Regions (2016-2021)
Table 14. Global Overactive Bladder Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 15. Global Overactive Bladder Drug Market Share by Regions (2022-2027)
Table 16. Overactive Bladder Drug Market Trends
Table 17. Overactive Bladder Drug Market Drivers
Table 18. Overactive Bladder Drug Market Challenges
Table 19. Overactive Bladder Drug Market Restraints
Table 20. Global Overactive Bladder Drug Revenue by Players (2016-2021) & (US$ Million)
Table 21. Global Overactive Bladder Drug Market Share by Players (2016-2021)
Table 22. Global Top Overactive Bladder Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder Drug as of 2020)
Table 23. Ranking of Global Top Overactive Bladder Drug Companies by Revenue (US$ Million) in 2020
Table 24. Global 5 Largest Players Market Share by Overactive Bladder Drug Revenue (CR5 and HHI) & (2016-2021)
Table 25. Key Players Headquarters and Area Served
Table 26. Key Players Overactive Bladder Drug Product Solution and Service
Table 27. Date of Enter into Overactive Bladder Drug Market
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 30. Global Overactive Bladder Drug Revenue Market Share by Type (2016-2021)
Table 31. Global Overactive Bladder Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 32. Global Overactive Bladder Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 33. Global Overactive Bladder Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 34. Global Overactive Bladder Drug Revenue Market Share by Application (2016-2021)
Table 35. Global Overactive Bladder Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 36. Global Overactive Bladder Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 37. North America Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 38. North America Overactive Bladder Drug Market Size by Type (2022-2027) & (US$ Million)
Table 39. North America Overactive Bladder Drug Market Size by Application (2016-2021) (US$ Million)
Table 40. North America Overactive Bladder Drug Market Size by Application (2022-2027) & (US$ Million)
Table 41. North America Overactive Bladder Drug Market Size by Country (2016-2021) & (US$ Million)
Table 42. North America Overactive Bladder Drug Market Size by Country (2022-2027) & (US$ Million)
Table 43. Europe Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 44. Europe Overactive Bladder Drug Market Size by Type (2022-2027) & (US$ Million)
Table 45. Europe Overactive Bladder Drug Market Size by Application (2016-2021) (US$ Million)
Table 46. Europe Overactive Bladder Drug Market Size by Application (2022-2027) & (US$ Million)
Table 47. Europe Overactive Bladder Drug Market Size by Country (2016-2021) & (US$ Million)
Table 48. Europe Overactive Bladder Drug Market Size by Country (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 50. Asia-Pacific Overactive Bladder Drug Market Size by Type (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Overactive Bladder Drug Market Size by Application (2016-2021) (US$ Million)
Table 52. Asia-Pacific Overactive Bladder Drug Market Size by Application (2022-2027) & (US$ Million)
Table 53. Asia-Pacific Overactive Bladder Drug Market Size by Region (2016-2021) & (US$ Million)
Table 54. Asia-Pacific Overactive Bladder Drug Market Size by Region (2022-2027) & (US$ Million)
Table 55. Latin America Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 56. Latin America Overactive Bladder Drug Market Size by Type (2022-2027) & (US$ Million)
Table 57. Latin America Overactive Bladder Drug Market Size by Application (2016-2021) (US$ Million)
Table 58. Latin America Overactive Bladder Drug Market Size by Application (2022-2027) & (US$ Million)
Table 59. Latin America Overactive Bladder Drug Market Size by Country (2016-2021) & (US$ Million)
Table 60. Latin America Overactive Bladder Drug Market Size by Country (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Overactive Bladder Drug Market Size by Type (2016-2021) (US$ Million)
Table 62. Middle East & Africa Overactive Bladder Drug Market Size by Type (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Overactive Bladder Drug Market Size by Application (2016-2021) (US$ Million)
Table 64. Middle East & Africa Overactive Bladder Drug Market Size by Application (2022-2027) & (US$ Million)
Table 65. Middle East & Africa Overactive Bladder Drug Market Size by Country (2016-2021) & (US$ Million)
Table 66. Middle East & Africa Overactive Bladder Drug Market Size by Country (2022-2027) & (US$ Million)
Table 67. Astellas Pharma, Inc. (Japan) Company Details
Table 68. Astellas Pharma, Inc. (Japan) Business Overview
Table 69. Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Product
Table 70. Astellas Pharma, Inc. (Japan) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 71. Astellas Pharma, Inc. (Japan) Recent Development
Table 72. Pfizer, Inc. (US) Company Details
Table 73. Pfizer, Inc. (US) Business Overview
Table 74. Pfizer, Inc. (US) Overactive Bladder Drug Product
Table 75. Pfizer, Inc. (US) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 76. Pfizer, Inc. (US) Recent Development
Table 77. Teva Pharmaceutical Industries Limited (Israel) Company Details
Table 78. Teva Pharmaceutical Industries Limited (Israel) Business Overview
Table 79. Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Product
Table 80. Teva Pharmaceutical Industries Limited (Israel) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 81. Teva Pharmaceutical Industries Limited (Israel) Recent Development
Table 82. Allergan, Plc (Ireland) Company Details
Table 83. Allergan, Plc (Ireland) Business Overview
Table 84. Allergan, Plc (Ireland) Overactive Bladder Drug Product
Table 85. Allergan, Plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 86. Allergan, Plc (Ireland) Recent Development
Table 87. Medtronic plc (Ireland) Company Details
Table 88. Medtronic plc (Ireland) Business Overview
Table 89. Medtronic plc (Ireland) Overactive Bladder Drug Product
Table 90. Medtronic plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 91. Medtronic plc (Ireland) Recent Development
Table 92. Mylan N.V. (US) Company Details
Table 93. Mylan N.V. (US) Business Overview
Table 94. Mylan N.V. (US) Overactive Bladder Drug Product
Table 95. Mylan N.V. (US) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 96. Mylan N.V. (US) Recent Development
Table 97. Endo International plc (Ireland) Company Details
Table 98. Endo International plc (Ireland) Business Overview
Table 99. Endo International plc (Ireland) Overactive Bladder Drug Product
Table 100. Endo International plc (Ireland) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 101. Endo International plc (Ireland) Recent Development
Table 102. Hisamitsu Pharmaceutical Co., Inc. (Japan) Company Details
Table 103. Hisamitsu Pharmaceutical Co., Inc. (Japan) Business Overview
Table 104. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 105. Hisamitsu Pharmaceutical Co., Inc. (Japan) Recent Development
Table 106. Sanofi (France) Company Details
Table 107. Sanofi (France) Business Overview
Table 108. Sanofi (France) Overactive Bladder Drug Product
Table 109. Sanofi (France) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 110. Sanofi (France) Recent Development
Table 111. Apotex, Inc. (Canada) Company Details
Table 112. Apotex, Inc. (Canada) Business Overview
Table 113. Apotex, Inc. (Canada) Overactive Bladder Drug Product
Table 114. Apotex, Inc. (Canada) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 115. Apotex, Inc. (Canada) Recent Development
Table 116. Cogentix Medical, Inc. (US) Company Details
Table 117. Cogentix Medical, Inc. (US) Business Overview
Table 118. Cogentix Medical, Inc. (US) Overactive Bladder Drug Product
Table 119. Cogentix Medical, Inc. (US) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 120. Cogentix Medical, Inc. (US) Recent Development
Table 121. Aurobindo Pharma Limited (India) Company Details
Table 122. Aurobindo Pharma Limited (India) Business Overview
Table 123. Aurobindo Pharma Limited (India) Overactive Bladder Drug Product
Table 124. Aurobindo Pharma Limited (India) Revenue in Overactive Bladder Drug Business (2016-2021) & (US$ Million)
Table 125. Aurobindo Pharma Limited (India) Recent Development
Table 126. Research Programs/Design for This Report
Table 127. Key Data Information from Secondary Sources
Table 128. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Overactive Bladder Drug Market Share by Type: 2020 VS 2027
Figure 2. Anticholinergics Features
Figure 3. Solifenacin Features
Figure 4. Oxybutynin Features
Figure 5. Darifenacin Features
Figure 6. Fesoterodine Features
Figure 7. Tolterodine Features
Figure 8. Trospium Features
Figure 9. Others Features
Figure 10. Global Overactive Bladder Drug Market Share by Application: 2020 VS 2027
Figure 11. Idiopathic Bladder Overactivity Case Studies
Figure 12. Neurogenic Bladder Overactivity Case Studies
Figure 13. Overactive Bladder Drug Report Years Considered
Figure 14. Global Overactive Bladder Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Overactive Bladder Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Overactive Bladder Drug Market Share by Regions: 2020 VS 2027
Figure 17. Global Overactive Bladder Drug Market Share by Regions (2022-2027)
Figure 18. Global Overactive Bladder Drug Market Share by Players in 2020
Figure 19. Global Top Overactive Bladder Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Overactive Bladder Drug as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Overactive Bladder Drug Revenue in 2020
Figure 21. Global Overactive Bladder Drug Revenue Market Share by Type (2016-2021)
Figure 22. Global Overactive Bladder Drug Revenue Market Share by Type (2022-2027)
Figure 23. North America Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Overactive Bladder Drug Market Share by Type (2016-2027)
Figure 25. North America Overactive Bladder Drug Market Share by Application (2016-2027)
Figure 26. North America Overactive Bladder Drug Market Share by Country (2016-2027)
Figure 27. United States Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Overactive Bladder Drug Market Share by Type (2016-2027)
Figure 31. Europe Overactive Bladder Drug Market Share by Application (2016-2027)
Figure 32. Europe Overactive Bladder Drug Market Share by Country (2016-2027)
Figure 33. Germany Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Overactive Bladder Drug Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Overactive Bladder Drug Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Overactive Bladder Drug Market Share by Region (2016-2027)
Figure 43. China Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Overactive Bladder Drug Market Share by Type (2016-2027)
Figure 51. Latin America Overactive Bladder Drug Market Share by Application (2016-2027)
Figure 52. Latin America Overactive Bladder Drug Market Share by Country (2016-2027)
Figure 53. Mexico Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Overactive Bladder Drug Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Overactive Bladder Drug Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Overactive Bladder Drug Market Share by Country (2016-2027)
Figure 59. Turkey Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Overactive Bladder Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Astellas Pharma, Inc. (Japan) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 63. Pfizer, Inc. (US) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 64. Teva Pharmaceutical Industries Limited (Israel) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 65. Allergan, Plc (Ireland) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 66. Medtronic plc (Ireland) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 67. Mylan N.V. (US) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 68. Endo International plc (Ireland) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 69. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 70. Sanofi (France) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 71. Apotex, Inc. (Canada) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 72. Cogentix Medical, Inc. (US) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 73. Aurobindo Pharma Limited (India) Revenue Growth Rate in Overactive Bladder Drug Business (2016-2021)
Figure 74. Bottom-up and Top-down Approaches for This Report
Figure 75. Data Triangulation
Figure 76. Key Executives Interviewed
世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Overactive Bladder Drug Market The global Overactive Bladder Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the re…- 世界の過活動膀胱治療薬市場 2021：企業別、地域別、種類・用途別 The Overactive Bladder Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…
- 世界の過活動膀胱治療薬市場規模・現状・予測（2021年-2027年） Overactive bladder (OAB) is a bladder disorder that results in an abnormal urge to urinate, urinary frequency, and nocturia (voiding at night). Some patients may also experience urinary incontinence (involuntary loss of bladder control). North America is the largest consumption market of Overactive …
- 世界の膀胱がん治療市場規模・現状・予測（2021年-2027年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…
- 世界の膀胱がん治療・診断市場規模・現状・予測（2021年-2027年） The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the inner…